Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
calcipotriol + betamethasone dipropionate
- Development stage
- Unknown
- Lead developer
- MC2 Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
GK664S (MC2-01) is a topical fixed-dose combination of calcipotriol and betamethasone dipropionate, formulated using the proprietary Polyaphron Dispersion (PAD) Technology. Developed by MC2 Therapeutics and licensed to Maruho for the Japanese market, the PAD technology enables the creation of a stable, aqueous-based cream that aims to improve skin penetration and patient convenience compared to traditional ointment-based treatments. Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor (VDR), regulating keratinocyte proliferation and differentiation. Betamethasone dipropionate is a potent corticosteroid that acts as a glucocorticoid receptor agonist, providing anti-inflammatory, antipruritic, and immunosuppressive effects. The product is marketed as Wynzora in the United States and Europe and is currently in Phase III clinical trials in Japan for the treatment of plaque psoriasis (psoriasis vulgaris).
- Brand names
- Wynzora
- Other names
- calcipotriene + betamethasone dipropionatecalcipotriol/betamethasone dipropionate PAD cream
02
Targets
VDR (Vitamin D receptor)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on calcipotriol + betamethasone dipropionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on calcipotriol + betamethasone dipropionate.